Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640523 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00640523: Completed Phase 2 study, sponsored by BioCryst Pharmaceuticals.
NCT00640523 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640523, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
To evaluate the effectiveness and safety of forodesine in CLL patients
Interventions
- DRUG forodesine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT00640523 record still lists
NCT00640523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which forodesine HCl is the first listed.
NCT00640523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00640523 about?
NCT00640523 is a clinical study titled "Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)". To evaluate the effectiveness and safety of forodesine in CLL patients
What is the current status of trial NCT00640523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00640523?
The interventions under investigation include: forodesine HCl (DRUG).
Who is sponsoring clinical trial NCT00640523?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00640523's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia